News

Johnson & Johnson Innovation Grant Aimed at Veteran Healthcare

A 2021 report by the U.S. Department of Health and Human Services found that Veterans are significantly more likely to develop multiple chronic health conditions in their lifetime like hypertension, arthritis, and cancer compared to non-Veterans. [1] To help treat wounded warriors and keep the military community healthy, we feel we must seek to identify and advance solutions with the potential to help address their medical needs.

To that end, Johnson & Johnson Innovation, together with Johnson & Johnson Office of Military and Veterans Affairs, is proud to continue the Veterans Lead QuickFire Challenge series. Innovators are invited to submit potentially ground-breaking ideas that aim to directly address the health care needs of the military community including cardiovascular disease [2], kidney disease [3], oncology [4], orthopedic and musculoskeletal disease [5], physical trauma management [6], respiratory health [7], and vision loss. [8]

The innovator(s) with the best idea, technology, or potential solution can receive grant funding from up to a total of $250,000, access to the Johnson & Johnson Innovation – JLABS ecosystem, and mentorship from experts across the Johnson & Johnson Family of Companies*.

* Subject to the execution of the necessary documentation and award agreement

 

Application Process

Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Uniqueness of the idea
  • Potential impact on human health, specifically the military-connected community’s health
  • Feasibility of the idea
  • Thoroughness of approach
  • Identification of key resources and plan to further idea

The challenge is now accepting applications. The deadline to apply is September, 17 2021.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these